Erratum: Impact of PSCAVariation on Gastric Ulcer Susceptibility (PLoS ONE (2013) 8:5 (e63698) DOI:10.1371/journal.pone.0063698);Impact of PSCA Variation on Gastric Ulcer Susceptibility

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Tanikawa, Chizu ^a   Matsuo, Keitaro ^b   Kubo, Michiaki ^c   Takahashi, Atsushi ^c   Ito, Hidemi ^b   Tanaka, Hideo ^b   Yatabe, Yasushi ^b   Yamao, Kenji ^b   Kamatani, Naoyuki ^c   Tajima, Kazuo ^b   Nakamura, Yusuke ^a,d   Matsuda, Koichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^d University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE STEM CELL ANTIGEN;

ABO GENE; ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PSCA GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ULCER;

EID: 84877957623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115366     Document Type: Erratum

References (43)

1. Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB (1993) Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan. Scand J Gastroenterol Suppl 200: 33-41.
2. Araki S, Goto Y, (1985) Peptic ulcer in male factory workers: a survey of prevalence, incidence, and aetiological factors. J Epidemiol Community Health 39: 82-85.
3. Schlesinger PK, Robinson B, Layden TJ, (1992) Epidemiology considerations in peptic ulcer disease. J Assoc Acad Minor Phys 3: 70-77.
4. Marshall BJ, (1994) Helicobacter pylori. Am J Gastroenterol 89: S116-128.
5. Hopkins RJ, Girardi LS, Turney EA, (1996) Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 110: 1244-1252.
6. Lu H, Hsu PI, Graham DY, Yamaoka Y, (2005) Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 128: 833-848.
7. Argent RH, Burette A, Miendje Deyi VY, Atherton JC, (2007) The presence of dupA in Helicobacter pylori is not significantly associated with duodenal ulceration in Belgium, South Africa, China, or North America. Clin Infect Dis 45: 1204-1206.
8. Wolfe MM, Lichtenstein DR, Singh G, (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899.
9. Chen TS, Lee YC, Li FY, Chang FY, (2005) Smoking and hyperpepsinogenemia are associated with increased risk for duodenal ulcer in Helicobacter pylori-infected patients. J Clin Gastroenterol 39: 699-703.
10. Kang JM, Kim N, Lee DH, Park JH, Lee MK, et al. (2009) The effects of genetic polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced gastroduodenal diseases in Korea. J Clin Gastroenterol 43: 420-428.
11. Lanas A, García-González MA, Santolaria S, Crusius JB, Serrano MT, et al. (2001) TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. Genes Immun 2: 415-421.
12. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, et al. (2007) Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med 20: 373-378.
13. Tanikawa C, Urabe Y, Matsuo K, Kubo M, Takahashi A, et al. (2012) A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. Nat Genet 44: 430-434, S431-432.
14. Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, et al. (2008) Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 40: 730-740.
15. de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, Nieuwenhuis EJ, Stigter-van Walsum M, et al. (2003) Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int J Cancer 103: 768-774.
16. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, et al. (2000) Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19: 1288-1296.
17. Marra E, Uva P, Viti V, Simonelli V, Dogliotti E, et al. (2010) Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer 10: 129.
18. Gu Z, Yamashiro J, Kono E, Reiter RE, (2005) Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res 65: 9495-9500.
19. Study Group of Millennium Genome Project for C, Sakamoto H, Yoshimura K, Saeki N, Katai H, et al (2008) Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 40: 730-740.
20. Bahrenberg G, Brauers A, Joost HG, Jakse G, (2000) Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem Biophys Res Commun 275: 783-788.
21. Saeki N, Gu J, Yoshida T, Wu X, (2010) Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 16: 3533-3538.
22. Nakai K, Kanehisa M, (1992) A knowledge base for predicting protein localization sites in eukaryotic cells. Genomics 14: 897-911.
23. Raff AB, Gray A, Kast WM, (2009) Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett 277: 126-132.
24. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H, (2003) Perforin and granzyme B of cytotoxic T lymphocyte mediate apoptosis irrespective of Helicobacter pylori infection: possible act as a trigger of peptic ulcer formation. Hepatogastroenterology 50: 1774-1779.
25. Kohaar I, Porter-Gill P, Lenz P, Fu YP, Mumy A, et al. (2013) Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer. J Natl Cancer Inst 105: 69-73.
26. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, et al. (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2: 1437-1442.
27. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, et al. (2008) Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372: 392-397.
28. Leung WK, Ng EK, Lam CC, Chan KF, Chan WY, et al. (2006) Helicobacter pylori infection in 1st degree relatives of Chinese gastric cancer patients. Scand J Gastroenterol 41: 274-279.
29. Brenner H, Bode G, Boeing H, (2000) Helicobacter pylori infection among offspring of patients with stomach cancer. Gastroenterology 118: 31-35.
30. Brenner H, Rothenbacher D, Bode G, Adler G, (1998) Parental history of gastric or duodenal ulcer and prevalence of Helicobacter pylori infection in preschool children: population based study. BMJ 316: 665.
31. Hatakeyama M, (2009) Helicobacter pylori and gastric carcinogenesis. J Gastroenterol 44: 239-248.
32. Yamaoka Y (2010) Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. England. pp. 629-641.
33. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, et al. (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69: 158-168.
34. Montalban C, Santon A, Boixeda D, Bellas C, (2001) Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication. Gut 49: 584-587.
35. Michel M, Cooper N, Jean C, Frissora C, Bussel JB, (2004) Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood 103: 890-896.
36. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G, (2007) The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 12Suppl 2: 32-38.
37. Nakamura Y, (2007) The BioBank Japan Project. Clin Adv Hematol Oncol 5: 696-697.
38. Kawaguchi T, Sho M, Tojo T, Yamato I, Nomi T, et al. (2010) Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn J Clin Oncol 40: 319-326.
39. Ono H, Hiraoka N, Lee YS, Woo SM, Lee WJ, et al. (2012) Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis. Genes Chromosomes Cancer 51: 30-41.
40. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, et al. (2011) Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 377: 383-392.
41. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, et al. (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41: 986-990.
42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
43. Breslow N, Day N (1987) Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ: 1-406.